{"doi":"10.1158/2767-9764.c.6708893.v2","title":"Data from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer","abstract":"<div><p>Pancreatic ductal adenocarcinoma (PDAC) is a significant contributor to cancer-related morbidity and mortality, and it is known for its resistance to conventional treatment regimens, including chemotherapy and immune checkpoint blockade (ICB)-based therapies. We have previously shown that Urolithin A (Uro A), a gut microbial metabolite derived from pomegranates, can target and inhibit <i>KRAS</i>-dependent PI3K/AKT/mTOR signaling pathways to overcome therapeutic resistance and improve survival in PDAC. However, the effect of Uro A on the tumor immune microenvironment and its ability to enhance ICB efficacy has not been explored. This study demonstrates that Uro A treatment reduces stromal fibrosis and reinvigorates the adaptive T-cell immune response to overcome resistance to PD-1 blockade in a genetically engineered mouse model (GEMM) of PDAC. Flow cytometric–based analysis of Uro A-treated mouse tumors revealed a significant attenuation of immunosuppressive tumor-associated M2-like macrophages with a concurrent increase in the infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells with memory-like phenotype along with reduced expression of the exhaustion-associated protein, PD-1. Importantly, the combination of Uro A treatment with anti-PD-1 immunotherapy promoted enhancement of the antitumor response with increased infiltration of CD4<sup>+</sup> Th1 cells, ultimately resulting in a remarkable improvement in overall survival in GEMM of PDAC. Overall, our findings provide preclinical evidence for the potential of Uro A as a novel therapeutic agent to increase sensitivity to immunotherapy in PDAC and warrant further mechanistic exploration in preclinical and clinical studies.</p>Significance:<p>Immunotherapeutic agents are ineffective against pancreatic cancer, mainly due to the immunosuppressive tumor microenvironment and stromal desmoplasia. Our current study demonstrates the therapeutic utility of a novel gut microbial metabolite, Uro A, to remodel the stromal-immune microenvironment and improve overall survival with anti-PD-1 therapy in pancreatic cancer.</p></div>","journal":null,"year":2023,"id":409498,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.954,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":280517,"name":"Vanessa T. Garrido","orcid":"0000-0002-5014-1608","position":1,"is_corresponding":false},{"id":814030,"name":"Austin R. Dosch","orcid":"0000-0001-9071-1591","position":2,"is_corresponding":false},{"id":814664,"name":"Purushottam Lamichhane","orcid":null,"position":3,"is_corresponding":false},{"id":352776,"name":"Supriya Srinivasan","orcid":"0009-0006-9320-6762","position":4,"is_corresponding":false},{"id":661634,"name":"Samara P. Singh","orcid":"0000-0002-5911-1499","position":5,"is_corresponding":false},{"id":814029,"name":"Zhiqun Zhou","orcid":"0000-0001-5248-8931","position":6,"is_corresponding":false},{"id":661635,"name":"Iago De Castro Silva","orcid":"0000-0002-3898-6173","position":7,"is_corresponding":false},{"id":1060666,"name":"C. Joshi","orcid":"0000-0003-0728-6550","position":8,"is_corresponding":false},{"id":620649,"name":"Yuguang Ban","orcid":"0000-0002-2874-0647","position":9,"is_corresponding":false},{"id":388184,"name":"Jashodeep Datta","orcid":"0000-0003-2869-1571","position":10,"is_corresponding":false},{"id":787965,"name":"Eli Gilboa","orcid":"0000-0002-2645-8154","position":11,"is_corresponding":false},{"id":336305,"name":"Nipun B. Merchant","orcid":"0000-0002-3399-9776","position":12,"is_corresponding":false},{"id":336304,"name":"Nagaraj S. Nagathihalli","orcid":"0000-0003-2373-3293","position":13,"is_corresponding":false},{"id":352775,"name":"Siddharth Mehra","orcid":"0000-0003-1639-8087","position":0,"is_corresponding":true}],"reference_count":31,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:21:27.199694Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}